Beyond the specific implications for B2M-mutant tumor patients and their response to ICB therapy, our study underlines the importance of better understanding the molecular characteristics of a tumor and their impact on patient’s prognosis when assessing the effect of certain therapies on patient’s survival. Here, B2M is linked to neoplasm.